The prevalence of sarcopenia ranges from 5.5–25.7%, and it is more prevalent in men than women ( 5). Primary sarcopenia is a manifestation of aging and is common in the elderly population, while secondary sarcopenia can be associated with reduced activity, disease, and malnutrition ( 6). Sarcopenia can be divided into primary and secondary sarcopenia. Under the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment, sarcopenia is defined as an age-related reduction in muscle mass, accompanied by a decrease in muscle strength and/or reduced physical performance ( 5). The concept of sarcopenia was first introduced by Rosenberg in 1989 ( 3) and was included in the International Classification of Disease 10th revision as a chronic muscle disease (M62.84) in 2016 ( 4). One study reported that after the age of 50, leg muscle mass decreases by 1–2% per year and muscle strength decreases by 1.5–5% per year ( 2). The aging process is characterized by a variety of changes in body composition for example, muscle mass peaks around the age of 30 and then begins to decline, with a loss of approximately 20–40% by the age of 70, and corresponding muscle dysfunction may occur ( 1). Keywords: Sarcopenia puerarin network pharmacology molecular mechanism signaling pathways Our study has laid a foundation for further studies on drug development and pharmacological experiments in the treatment of sarcopenia. Further, the GO and KEGG analyses revealed that the functions of the core targets and related pathways were mainly associated with the cell cycle, apoptosis, protein synthesis, and proteolysis.Ĭonclusions: Puerarin has the potential to treat sarcopenia through the regulation of the cell cycle, apoptosis, and protein homeostasis. A total of 206 core targets, which were considered potential therapeutic targets, were identified from the merged PPI network. Results: We identified 53 targets for puerarin and 129 targets for sarcopenia. The results were visualized using an online bioinformatics tool. To determine the potential targeting pathways, the core targets were further imported into the Metascape platform for the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The protein-protein interaction (PPI) network was generated by BisoGenet, and core targets were identified by a topological analysis. Methods: The potential therapeutic targets of puerarin were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database, while the targets of sarcopenia were obtained from the GeneCards, DisGeNET, Online Mendelian Inheritance in Man (OMIM), and Therapeutic Target Database (TTD) databases. This study adopted a network pharmacological approach to explore the possible mechanisms of puerarin in treating sarcopenia. Thus, effective treatments urgently need to be developed to slow down the development of sarcopenia. Policy of Dealing with Allegations of Research Misconductīackground: With the acceleration of population aging, sarcopenia will place a heavy burden on families and society.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |